Investigators compared risk prediction using PathomIQ's platform to molecular test results, evaluating its ability to predict biochemical recurrence in high-risk patients.

Health Canada has allowed the firm to bypass a requirement that tests be authorized for non-professional use prior to self-test authorization.

The Tulane team has developed a handful of other assays for TB detection, including a mass spec test for paucibacillary TB ...

Broader macroeconomic uncertainty has resulted in continued cautiousness for both investors and acquirers in the in vitro ...

NEW YORK – With the recent completion of a multisite study in Europe and the opening of a lab in Tennessee, Glasgow, Scotland-based liquid biopsy developer Dxcover plans to launch its infrared ...

A lab owner, marketing firm owner, and doctor have been sentenced to between 13 months and five years in prison for their roles in a multimillion-dollar lab fraud scheme.

Lund, Sweden-based Qlucore aims to have bladder cancer and AML tests available for clinical use in Europe by 2027.

NEW YORK — Canadian diagnostics developer Nanostics said Thursday that it has received a C$3.8 million (US$2.8 million) grant from Genome Canada and Genome Alberta to boost the adoption of its ...

The firm is seeking marketing clearance for its Liaison NES real-time PCR instrument along with a multiplex test for flu A/B, COVID-19, and respiratory syncytial virus infection.